253 related articles for article (PubMed ID: 29622375)
1. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
3. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
4. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
5. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
6. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
7. Aquagenic pruritus and the JAK2 V617F mutation.
Langabeer SE
Clin Exp Dermatol; 2019 Apr; 44(3):e33. PubMed ID: 30578575
[No Abstract] [Full Text] [Related]
8. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
9. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
10. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
11. JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applications.
Tefferi A
N Engl J Med; 2007 Feb; 356(5):444-5. PubMed ID: 17267904
[No Abstract] [Full Text] [Related]
12. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
13. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
14. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
Mahfouz RA; Hoteit R; Salem Z; Bazarbachi A; Mugharbel A; Farhat F; Ziyadeh A; Ibrahim A; Taher A
Genet Test Mol Biomarkers; 2011 Apr; 15(4):263-5. PubMed ID: 21198321
[TBL] [Abstract][Full Text] [Related]
17. The JAK2(V617F) tyrosine kinase mutation in blood donors with upper-limit haematocrit levels.
Tagariello G; Di Gaetano R; Sartori R; Zanotto D; Belvini D; Radossi P; Risato R; Roveroni G; Salviato R; Tassinari C; Toffano N
Blood Transfus; 2009 Apr; 7(2):111-6. PubMed ID: 19503632
[TBL] [Abstract][Full Text] [Related]
18. An inherited gain-of-function risk allele in EPOR predisposes to familial JAK2
Rabadan Moraes G; Pasquier F; Marzac C; Deconinck E; Damanti CC; Leroy G; El-Khoury M; El Nemer W; Kiladjian JJ; Raslova H; Najman A; Vainchenker W; Marty C; Bellanné-Chantelot C; Plo I
Br J Haematol; 2022 Jul; 198(1):131-136. PubMed ID: 35355248
[TBL] [Abstract][Full Text] [Related]
19. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
